New Front Opens in First-Line Ovarian Cancer Market: GSK’s Zejula Vs. AZ’s Lynparza

 
• By Alexandra Shimmings

Two new PARP inhibitor studies – GSK’s PRIMA and AstraZeneca/Merck & Co.’s PAOLA-1  – are set to widen the ovarian cancer market after they reported highly positive first-line results in advanced patients at ESMO.

OvarianCancer_1200x675
Cures are elusive in first-line ovarian cancer, but two PARP inhibitors improved progression-free surivival. • Source: Shutterstock

More from Clinical Trials

More from R&D